Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
← catalyst calendarNCT06553768 · readout ≤ 72 d
Sponsored by Mirum Pharmaceuticals, Inc. (industry) · MIRM — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
90estimated
Sites
24
Countries
Brazil, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-14 | actual | When the study began enrolling |
| Primary completion | Oct 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
- Drug: Maralixibat — also filed as Formerly LUM001, SHP625
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFMean change in the ItchRO(Obs) severity score
measured From baseline to average of week 13 to week 20
Permalink · MIRM's whole pipeline · Catalyst calendar · Every registered study · What changed